IMGN

ImmunoGen, Inc. Press Releases

$9.26
*  
0.26
2.89%
Get IMGN Alerts
*Delayed - data as of Oct. 23, 2014 11:53 ET  -  Find a broker to begin trading IMGN now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    IMGN Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By
Ipsen Announces Positive Results from Phase III Clinical Study of Decapeptyl® (triptorelin pamoate) 11.25 mg Administered by Subcutaneous Route to Prostate Cancer Patients
10/10/2014 11:30:00 AM - Business Wire


ImmunoGen, Inc. Announces Conference Call to Discuss Its First Quarter Fiscal Year 2015 Financial Results
10/10/2014 11:30:00 AM - Business Wire
▲1.76 % Price Change since this news event. The Volume Ratio is 0.93.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


ImmunoGen, Inc. Hires Sandra E. Poole as Senior Vice President of Technical Operations
9/15/2014 8:30:00 AM - Business Wire


ImmunoGen, Inc. Announces Morgan Stanley Global Healthcare Conference Webcast
9/2/2014 4:15:00 PM - Business Wire


ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences
8/4/2014 2:45:00 PM - Business Wire


ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2014 Financial Results
8/1/2014 6:30:00 AM - Business Wire